49 related articles for article (PubMed ID: 19221150)
1. Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer.
Chen H; Horita N; Ito K; Hara Y; Kobayashi N; Kaneko T
Transl Lung Cancer Res; 2020 Aug; 9(4):1333-1342. PubMed ID: 32953508
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer.
Cooper K; Tappenden P; Cantrell A; Ennis K
Br J Cancer; 2020 Nov; 123(11):1686-1696. PubMed ID: 32913287
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer.
Fukui T; Itabashi M; Ishihara M; Hiyoshi Y; Kasajima M; Igawa S; Sasaki J; Masuda N
BMC Cancer; 2016 Mar; 16():197. PubMed ID: 26955807
[TBL] [Abstract][Full Text] [Related]
4. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.
Hotta K; Kato Y; Leighl N; Takigawa N; Gaafar RM; Kayatani H; Hirata T; Ohashi K; Kubo T; Tabata M; Tanimoto M; Kiura K
PLoS One; 2015; 10(3):e0121211. PubMed ID: 25775395
[TBL] [Abstract][Full Text] [Related]
5. Clinical considerations for the development of biosimilars in oncology.
Socinski MA; Curigliano G; Jacobs I; Gumbiner B; MacDonald J; Thomas D
MAbs; 2015; 7(2):286-93. PubMed ID: 25621390
[TBL] [Abstract][Full Text] [Related]
6. Metabolic burden measured by (18)f-fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in patients with small cell lung cancer.
Kim MH; Lee JS; Mok JH; Lee K; Kim KU; Park HK; Kim SJ; Lee MK
Cancer Res Treat; 2014 Apr; 46(2):165-71. PubMed ID: 24851108
[TBL] [Abstract][Full Text] [Related]
7. Expert perspectives on biosimilar monoclonal antibodies in breast cancer.
Cortés J; Curigliano G; Diéras V
Breast Cancer Res Treat; 2014 Apr; 144(2):233-9. PubMed ID: 24562824
[TBL] [Abstract][Full Text] [Related]
8. Lung cancer stem cells: a biological and clinical perspective.
Koren A; Motaln H; Cufer T
Cell Oncol (Dordr); 2013 Jul; 36(4):265-75. PubMed ID: 23900738
[TBL] [Abstract][Full Text] [Related]
9. Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades.
Ochi N; Hotta K; Takigawa N; Oze I; Fujiwara Y; Ichihara E; Hisamoto A; Tabata M; Tanimoto M; Kiura K
PLoS One; 2012; 7(8):e42798. PubMed ID: 22880112
[TBL] [Abstract][Full Text] [Related]
10. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review.
Hotta K; Kiura K; Fujiwara Y; Takigawa N; Hisamoto A; Ichihara E; Tabata M; Tanimoto M
PLoS One; 2011; 6(11):e26646. PubMed ID: 22114662
[TBL] [Abstract][Full Text] [Related]
11. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
12. [Implications of modern anticancer therapies for palliative care concepts].
Alt-Epping B; Nauck F
Schmerz; 2010 Dec; 24(6):633-41. PubMed ID: 20882301
[TBL] [Abstract][Full Text] [Related]
13. Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer.
Hotta K; Kiura K; Fujiwara Y; Takigawa N; Oze I; Ochi N; Tabata M; Tanimoto M
Ann Oncol; 2009 May; 20(5):829-34. PubMed ID: 19221150
[TBL] [Abstract][Full Text] [Related]
14. Extensive-stage small-cell lung cancer--moving beyond response rate?
Ferraldeschi R; Lorigan P
Ann Oncol; 2009 May; 20(5):801-2. PubMed ID: 19403933
[No Abstract] [Full Text] [Related]
15. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results.
Oze I; Hotta K; Kiura K; Ochi N; Takigawa N; Fujiwara Y; Tabata M; Tanimoto M
PLoS One; 2009 Nov; 4(11):e7835. PubMed ID: 19915681
[TBL] [Abstract][Full Text] [Related]
16. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials.
Hotta K; Fujiwara Y; Kiura K; Takigawa N; Tabata M; Ueoka H; Tanimoto M
J Thorac Oncol; 2007 May; 2(5):402-7. PubMed ID: 17473655
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for small-cell lung cancer.
Metro G; Cappuzzo F
Expert Opin Emerg Drugs; 2009 Dec; 14(4):591-606. PubMed ID: 19694501
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
